tbuckley/cabot-search huggingface dataset:
SAT0250 A Tailored Approach to Reduce Dose of Anti-TNF Drugs is Equally Effective and Less Costly Than Standard Dosing in Patients with Ankylosing Spondylitis Over Two Years: A Propensity Score-Matched Cohort Study
Authors: J. Zavada, M. Uher, K. Sisol, S. Forejtova, K. Jarosova, H. Mann, J. Vencovsky, K. Pavelka
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Objectives</h3> To compare effectiveness, safety and costs of standard versus individually tailored reduced doses of anti-TNF drugs in patients with Ankylosing Spondylitis (AS) after achieving low disease activity. <h3>Methods</h3> This was a single center prospective observational study performed within the national biologics registry. The anti-TNF dose tapering strategy was chosen by treating physicians, without pre-specified protocol. We used propensity score (PS) methodology to identify 2 cohorts of patients matched for relevant baseline characteristics (age, gender, baseline activity, baseline function, disease duration, duration of anti-TNF therapy - see table) who were treated with either reduced (n=53) or standard (n=83) doses of TNF inhibitors. Two years outcomes and costs of anti-TNF drugs were compared between both PS-matched cohorts. <h3>Results</h3> In the reduced dosing group the median dose of TNF inhibitor corresponded to 0.67, and 0.58 of the standard dose initially, and at 24 months resp., and 23% of patients required return to standard dosing regimen. The hazard ratio (95% CI) of reduced versus standard dosing group for relapse and any adverse event was 1.25 (0.68; 2.28), and 0.61 (0.31; 1.19) resp. (Figure). The mean change per 2 years in BASFI, as well as BASDAI and CRP area under the curve (AUC) were no different between both groups, but the cost for anti-TNF drugs was substantially lower in the reduced dosing group (table). <h3>Conclusions</h3> In AS patients after reaching low disease activity a tailored approach to reduce doses of anti-TNF drugs produced similar clinical outcomes at 2 years, but was substantially less costly. <h3>Acknowledgements</h3> Supported by project of MHCR for conceptual development of research organization 023728 <h3>Disclosure of Interest</h3> None declared
PTH-132 Outcomes following transplant for hepatitis c: a single centre study
Authors: SA Townsend, H Dhaliwal, B Gunson, D Mutimer
Journal: Gut (2015)

<h3>Introduction</h3> Liver disease from hepatitis C (HCV) is a leading indication for liver transplantation in the UK. HCV recurrence has a significant influence on graft and patient survival, but antiviral therapy has had poor tolerability and disappointing efficacy (low sustained virological response SVR rates) in the transplant setting. The use of antivirals has evolved over time, from interferon (IFN) monotherapy to combination IFN and ribavirin, and now includes the frequent use of direct acting antiviral drugs (DAAs), often as components of IFN-free regimens. We examined the outcome of 431 patients with hepatitis C who underwent liver transplantation at the Queen Elizabeth Hospital, Birmingham, and report the outcome of treatment and its possible effect on graft and patient survival. <h3>Method</h3> Retrospective study of all patients transplanted for HCV at the Queen Elizabeth Liver Transplant Unit, Birmingham. <h3>Results</h3> 431 patients with HCV were transplanted between 1988 and 2014. 174 patients had hepatocellular carcinoma (HCC) and 81 also had alcohol-related damage as a cofactor. 91 were female (21%) and 340 male (79%), with a mean age of 52 years at transplantation (range 27–69). Patient survival rates were 88%, 68% and 48%, at 1, 5 and 10 years respectively; graft survival was 86%, 65% and 46% for the same time intervals. The commonest causes of death were HCV recurrence n = 34 (20%), sepsis n = 33 (19%), recurrent HCC n = 30 (17%), and gastrointestinal bleeding n = 10 (5%). 28 patients required regrafting. The indications were recurrent disease n = 11 (39%), primary non-function n = 8 (29%), hepatic artery thrombosis n = 8 (29%), and chronic rejection n = 1 (3%). 109 patients received 118 courses of antiviral treatment post-transplant. 20 (17%) of these were IFN monotherapy, 61 (52%) IFN and ribavirin, 12 (10%) triple therapy with IFN, ribavirin and telapravir, and the remaining 25 (21%) were DDAs. The overall SVR rate was 57%. Those patients achieving SVR had significantly better survival than those who failed treatment, and also better than those never treated (5 year patient survival 95%, 72%, 62% respectively, p &lt; 0.001). No difference in overall survival was observed between HCV genotypes (p = 0.1). <h3>Conclusion</h3> Successful antiviral treatment is associated with superior patient survival in transplanted HCV patients. However, a minority (25%) of patients were considered suitable for treatment. Newly licensed DAAs have superior efficacy and good tolerability in the post-transplant setting. Going forward, the use of DAAs is predicted to have a major impact on graft and patient survival. <h3>Disclosure of interest</h3> None Declared.
THU0276 Comparison of Two Different Scoring Methods for the Evaluation of Articular and Vascular FDG-PET/CT Uptake in PMR Patients
Authors: D. Camellino, F. Paparo, S. Morbelli, M. Cutolo, G. Sambuceti, M.A. Cimmino
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Polymyalgia rheumatica (PMR) is an inflammatory disease of the elderly characterized by girdle pain and systemic symptoms. Imaging techniques, such as 18F-fluorodesoxyglucose (FDG)-PET/CT, have demonstrated that inflammation is localized mainly in the joint capsule and in bursae, with possible associated large vessel vasculitis (1). 18F-FDG PET/CT readings of the intensity of the glucose analogue uptake in joints and vessels are scarcely standardized, however (2). <h3>Objectives</h3> To compare a visual, semi-quantitative score for articular and vascular FDG uptake in PMR patients, with a quantitative one based on standardized uptake value (SUV). <h3>Methods</h3> Eighty-four consecutive PMR patients, diagnosed according to Bird9s criteria, underwent PET/CT after a standardized clinical examination. None of them fulfilled the ACR criteria for GCA. Joint and vascular uptake was scored both semi-quantitatively with a visual score and quantitatively. The visual score used a four-point scale (visual joint score, VJS and visual vascular score, VVS): 0=no uptake present, 1=uptake present but lower than liver uptake, 2=similar to liver uptake, 3=uptake higher than liver uptake. Regions of interest (ROIs) were drawn on the theoretical arterial wall and within the left ventricular chamber (blood-pool, BP). Arterial FDG uptake was quantified by calculating the mean standardized uptake value (SUV) within each ROI and the results expressed as the ratio between mean SUV value of each ROI and BP ROI (SUV/BP). To assess joint metabolism, CT-based ROIs were bilaterally drawn on joint and bursal spaces. The normal cut-off was derived from the mean+2SD of the SUV in each district of 84 sex- and age-matched controls: it was1.8 for joints and of 1.6 for arteries. <h3>Results</h3> Results are reported in table 1 (see image 1). There was no correlation between sites of provoked pain at clinical examination and VJS or joint median SUV. <h3>Conclusions</h3> Visual semi-quantitative and quantitative scores correlated only at joint level, but the percentage of positive areas was higher with the first method. Although a quantitative assessment could offer the theoretical advantage of being objective, reproducible and operator-independent, it underestimated both articular and vascular pathological findings. <h3>References</h3> Camellino D, Cimmino MA. Imaging of polymyalgia rheumatica: indications on its pathogenesis, diagnosis and prognosis. Rheumatology (Oxford) 2012;51:77-86. Puppo C, Massollo M, Paparo F, Camellino D, Piccardo A, Shoushtari Zadeh Naseri M, Villavecchia G, Rollandi GA, Cimmino MA. Giant cell arteritis: a systematic review of the qualitative and semiquantitative methods to assess vasculitis with 18F-fluorodeoxyglucose positron emission tomography. Biomed Res Int. 2014. Epub 2014 Sep 1. <h3>Disclosure of Interest</h3> None declared
Expression of Genes for Intracisternal A-Particle Antigen in Somatic Cell Hybrids
Authors: John D. Minna, Kira K. Lueders, Edward L. Kuff
Journal: JNCI Journal of the National Cancer Institute (1974)

Journal Article Expression of Genes for Intracisternal A-Particle Antigen in Somatic Cell Hybrids Get access John D. Minna, John D. Minna Search for other works by this author on: Oxford Academic PubMed Google Scholar Kira K. Lueders, Kira K. Lueders Search for other works by this author on: Oxford Academic PubMed Google Scholar Edward L. Kuff Edward L. Kuff Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 52, Issue 4, April 1974, Pages 1211–1217, https://doi.org/10.1093/jnci/52.4.1211 Published: 01 April 1974 Article history Received: 20 September 1973 Accepted: 03 January 1974 Published: 01 April 1974
Experiments on an Ascites Hepatoma. III. The Conversion of Mouse Hepatomas into the Ascites Form
Authors: Haruo Sato, Morris Belkin, Edward Essner
Journal: JNCI Journal of the National Cancer Institute (1956)

Journal Article Experiments on an Ascites Hepatoma. III. The Conversion of Mouse Hepatomas into the Ascites Form Get access Haruo Sato, Haruo Sato Laboratory of Chemical Pharmacology, National Cancer Institute,4Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar Morris Belkin, Morris Belkin Laboratory of Chemical Pharmacology, National Cancer Institute,4Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar Edward Essner Edward Essner Laboratory of Chemical Pharmacology, National Cancer Institute,4Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 17, Issue 1, July 1956, Pages 1–21, https://doi.org/10.1093/jnci/17.1.1 Published: 01 July 1956 Article history Received: 01 February 1956 Published: 01 July 1956
Re: Jeffrey J. Tosoian, Debasish Sundi, Bruce J. Trock, et al. Pathologic Outcomes in Favorable-risk Prostate Cancer: Comparative Analysis of Men Electing Active Surveillance and Immediate Surgery. Eur Urol 2016;69:576–81
Authors: Weigang Yan, Zhien Zhou, Hanzhong Li
Journal: European Urology (2016)
Polymerase chain reaction: the molecular microscope of residual disease.
Authors: J Sklar
Journal: Journal of Clinical Oncology (1991)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1991.9.9.1521 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 1875214 Polymerase chain reaction: the molecular microscope of residual disease. J SklarxJ SklarSearch for articles by this author https://doi.org/10.1200/JCO.1991.9.9.1521 First Page PDF © 1991 by American Society of Clinical Oncology
Comparison of CT and integrated PET-CT-based gross tumor volume delineation for radiotherapy in patients with pancreatic carcinoma.
Authors: N. Liu, Z. Yuan, Y. Xu, L. Zhu, Bailin Zhang, Jinqiang You, Jian Sun, None Chengwen, None yang, Lujun Zhao
Journal: Journal of Clinical Oncology (2010)

e14635 Background: Accurate target volume delineation remains to be one of the most important factors for radiotherapy (RT) in locally advanced or medically inoperable pancreatic carcinoma (PC). This investigation compares CT with coregistered 18F-FDG PET-CT as the basis for delineating gross tumor volume (GTV) in PC. Methods: Nonenhanced CT scan, enhanced CT scan and co-registered PET-CT data of 21 histologically proved PC patients were retrospectively utilized. Sets of 5 GTVs were generated for each case: GTVCT-nonenhanced and GTVCT-enhanced were delineated by applying standard windows. GTVPET was delineated automatically by an isocontour of maximum standardized uptake value (SUVmax) 2.5 around the tumor. GTVPET-CT-enhanced or GTVPET-CT-nonenhanced was generated according to the combination of GTVPET and GTVCT. Results: The mean GTVCT-nonenhanced, GTVCT-enhanced, GTVPET, GTVPET-CT-nonenhanced and GTVPET-CT-enhanced were 102.9 ± 35.8, 98.0 ± 37.7, 106.6 ± 37.1, 131.0 ± 40.7, and 123.4 ± 41.6 cm3, respectively. In 17 of 21 patients, compared to nonenhanced CT, enhanced CT-based GTV resulted in a significant decrease (10.7% ± 7.5%, p = 0.03). In 4 patients, GTV were increased due to the incorporation of additional lymph node metastasis (1 patient) and extension of the primary tumor (3 patients) based on PET information. The difference between GTVCT-non-enhanced, GTVCT-enhanced and GTVPET was not statistically significant (p = 0.09) whereas the difference between GTVCT-no- enhanced, GTVCT-enhanced, GTVPET and composite volume (GTVPET-CT-enhanced or GTVPET-CT- nonenhanced) were significant (p < 0.001). Interestingly, a significant difference was showed between GTVCT-nonenhanced, GTVCT-enhanced and GTVPET when the maximum tumor diameter was less than 5 cm. Conclusions: This study demonstrated that integrated PET-CT, especially integration of enhanced CT scan, may greatly improve the delineation of GTV in PC. Theoretically, tumor control rates may potential be increased which needs to be tested in future studies. No significant financial relationships to disclose.
Phosphorylation state–dependent modulation of spinal glycine receptors alleviates inflammatory pain
Authors: Mario A. Acuña, Gonzalo E. Yévenes, William T. Ralvenius, Dietmar Benke, Alessandra Di Lio, Cesar O. Lara, Braulio Muñoz, Carlos F. Burgos, Gustavo Moraga-Cid, Pierre-Jean Corringer, Hanns Ulrich Zeilhofer
Journal: Journal of Clinical Investigation (2016)

Diminished inhibitory neurotransmission in the superficial dorsal horn of the spinal cord is thought to contribute to chronic pain. In inflammatory pain, reductions in synaptic inhibition occur partially through prostaglandin E2- (PGE2-) and PKA-dependent phosphorylation of a specific subtype of glycine receptors (GlyRs) that contain α3 subunits. Here, we demonstrated that 2,6-di-tert-butylphenol (2,6-DTBP), a nonanesthetic propofol derivative, reverses inflammation-mediated disinhibition through a specific interaction with heteromeric αβGlyRs containing phosphorylated α3 subunits. We expressed mutant GlyRs in HEK293T cells, and electrophysiological analyses of these receptors showed that 2,6-DTBP interacted with a conserved phenylalanine residue in the membrane-associated stretch between transmembrane regions 3 and 4 of the GlyR α3 subunit. In native murine spinal cord tissue, 2,6-DTBP modulated synaptic, presumably αβ heteromeric, GlyRs only after priming with PGE2. This observation is consistent with results obtained from molecular modeling of the α-β subunit interface and suggests that in α3βGlyRs, the binding site is accessible to 2,6-DTBP only after PKA-dependent phosphorylation. In murine models of inflammatory pain, 2,6-DTBP reduced inflammatory hyperalgesia in an α3GlyR-dependent manner. Together, our data thus establish that selective potentiation of GlyR function is a promising strategy against chronic inflammatory pain and that, to our knowledge, 2,6-DTBP has a unique pharmacological profile that favors an interaction with GlyRs that have been primed by peripheral inflammation.
Bone Marrow Metastases in Breast Cancer
Authors: E Pikarsky, T Peretz
Journal: New England Journal of Medicine (2000)

To the Editor: In their study of the histochemical detection of metastases from breast cancer to bone marrow, Braun et al. (Feb.24 issue) 1 found that multivariate analysis identified the presence of cytokeratin-positive cells in the bone marrow as an independent predictor of survival.What do the authors think about the use of flow cytometry after cytokeratin staining?Their results clearly demonstrate that the presence of cytokeratin-positive cells in the bone marrow of patients with breast carcinoma is associated with shorter survival.However, because cytokeratin-positive cells were detected in control patients with nonmalignant disease and stage I tumors had fewer than 5 cytokeratin-positive cells per 2¬10 6 bone marrow cells, the authors should also clarify the threshold of positivity needed to avoid false positive results.Braun et al. found a median of 3 cytokeratin-positive cells per 2¬10 6 bone marrow cells, but the exclusion of patients with fewer than 3 cytokeratin-positive cells per 2¬10 6 bone marrow cells would not be enough, because the confidence interval for each stage is not mentioned.
An Antidote to Parathion Poisoning
Authors: E E ROSENBAUM, R J HERSCHLER, S W JACOB
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Case 40-1980
Authors: Richard C. Cabot, Robert E. Scully, James J. Galdabini, Betty U. McNeely, Howard D. Dorfman, Alan L. Schiller
Journal: New England Journal of Medicine (1980)

Presentation of CaseAn 18-year-old man was admitted to the hospital because of a mass in the right groin.He was well until six months earlier, when he experienced pain in the right groin, which was initially mild and intermittent but gradually increased in severity and caused him to limp. During the next three months the pain extended into the right thigh and interfered with rest. Crutches and antiinflammatory agents were prescribed, without benefit. Three months before admission he entered another hospital, where examination showed a mass in the right hip. X-ray films and tomographic examination of the pelvis ( . . .
Effect of Discontinued Estrogenic Stimulation upon the Development and Growth of Testicular Tumors in Mice
Authors: Andervont, Howard B., Shimkin, Michael B., Canter, Harry Y.
Journal: JNCI Journal of the National Cancer Institute (1957)

Journal Article Effect of Discontinued Estrogenic Stimulation upon the Development and Growth of Testicular Tumors in Mice Get access Howard B. Andervont, Howard B. Andervont Laboratory of Biology and Biometry and Epidemiology Branch, National Cancer Institute,2Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar Michael B. Shimkin, Michael B. Shimkin Laboratory of Biology and Biometry and Epidemiology Branch, National Cancer Institute,2Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar Harry Y. Canter Harry Y. Canter Laboratory of Biology and Biometry and Epidemiology Branch, National Cancer Institute,2Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 18, Issue 1, January 1957, Pages 1–39, https://doi.org/10.1093/jnci/18.1.1 Published: 01 January 1957 Article history Received: 27 August 1956 Published: 01 January 1957
The new face of enterohaemorrhagic Escherichia coli infections
Authors: A Jansen, J T Kielstein
Journal: Eurosurveillance (2011)

Preview this article: The new face of enterohaemorrhagic Escherichia coli infections, Page 1 of 1 < Previous page | Next page > /docserver/preview/fulltext/eurosurveillance/16/25/art19898-en-1.gif
PREVENTION OF HIGH FATALITY RATE IN SERUM HEPATITIS
Authors: O E AUFRANC, W N JONES, W H HARRIS
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Safety, tolerability, and immunogenicity of a recombinant toxic shock syndrome toxin (rTSST)-1 variant vaccine: a randomised, double-blind, adjuvant-controlled, dose escalation first-in-man trial
Authors: Michael Schwameis, Bernhard Roppenser, Christa Firbas, Corina S Gruener, Nina Model, Norbert Stich, Andreas Roetzer, Nina Buchtele, Bernd Jilma, Martha M Eibl
Journal: The Lancet Infectious Diseases (2016)